FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 732 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Working to Make Cancer Clinical Trials More Inclusive: A Q&A With... October 6, 2022 How to Find the Right Hospice Care Program for You or... August 10, 2023 The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer... September 20, 2021 7 Practical Tips for Taking Long-Term Medication January 9, 2024 Load more HOT NEWS Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations [ESMO Press... Veteran and His Loyal Dog Pass Away Within Hours Of Each... Talquetamab Continuous To Demonstrate High Overall Response Rates in Heavily Pretreated... Coping With the Difficult Times of Cancer Survivorship Through My “Bucket...
